Neoadjuvant Pembrolizumab

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

March 19, 2019

Study Completion Date

March 31, 2026

Conditions
Non-small Cell Lung Carcinoma
Interventions
DRUG

Pembrolizumab

"Pembrolizumab (prior to surgery) 200 mg IV over 30 min, days 1 \& 22, two cycles; followed by surgery; followed by standard adjuvant chemotherapy (per med. oncologist) +/- radiation therapy per institutional standard of care; followed by adjuvant pembrolizumab 200 mg IV over 30 min every 21 days for 4 cycles~-Note: Standard radiation therapy in selected patients for standard clinical indications"

Trial Locations (3)

27710

Duke University Medical Center, Durham

55905

Mayo Clinic, Rochester

03756

Dartmouth-Hitchcock Medical Center, Lebanon

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Neal Ready MD PhD

OTHER